Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

This multinational, randomized trial compared oral apixaban with subcutaneous dalteparin for treating venous thromboembolism (VTE) in cancer patients. Apixaban was noninferior to dalteparin in preventing recurrent VTE (5.6% vs. 7.9%; hazard ratio 0.63) without increasing major bleeding risk (3.8% vs. 4.0%). The study supports apixaban as a safe and effective alternative to low-molecular-weight heparin in this population.

This multinational, randomized trial compared oral apixaban with subcutaneous dalteparin for treating venous thromboembolism (VTE) in cancer patients. Apixaban was noninferior to dalteparin in preventing recurrent VTE (5.6% vs. 7.9%; hazard ratio 0.63) without increasing major bleeding risk (3.8% vs. 4.0%). The study supports apixaban as a safe and effective alternative to low-molecular-weight heparin in this population.